| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | LCP2 |
| Uniprot No | Q13094 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-533aa |
| 氨基酸序列 | MALRNVPFRSEVLGWDPDSLADYFKKLNYKDCEKAVKKYHIDGARFLNLT ENDIQKFPKLRVPILSKLSQEINKNEERRSIFTRKPQVPRFPEETESHEE DNGGWSSFEEDDYESPNDDQDGEDDGDYESPNEEEEAPVEDDADYEPPPS NDEEALQNSILPAKPFPNSNSMYIDRPPSGKTPQQPPVPPQRPMAALPPP PAGRNHSPLPPPQTNHEEPSRSRNHKTAKLPAPSIDRSTKPPLDRSLAPF DREPFTLGKKPPFSDKPSIPAGRSLGEHLPKIQKPPLPPTTERHERSSPL PGKKPPVPKHGWGPDRRENDEDDVHQRPLPQPALLPMSSNTFPSRSTKPS PMNPLPSSHMPGAFSESNSSFPQSASLPPYFSQGPSNRPPIRAEGRNFPL PLPNKPRPPSPAEEENSLNEEWYVSYITRPEAEAALRKINQDGTFLVRDS SKKTTTNPYVLMVLYKDKVYNIQIRYQKESQVYLLGTGLRGKEDFLSVSD IIDYFRKMPLLLIDGKNRGSRYQCTLTHAAGYP |
| 预测分子量 | 85 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于LCP2重组蛋白的参考文献示例(注：以下内容为模拟虚构，实际文献需通过学术数据库检索确认)：
---
1. **文献名称**：*Recombinant LCP2 Expression in E. coli and Its Role in T Cell Receptor Signaling*
**作者**：Chen L, Wang Y, et al.
**摘要**：本研究利用大肠杆菌系统成功表达并纯化了重组LCP2蛋白，通过体外磷酸化实验证实其参与TCR下游信号通路的活化，并揭示了其与ZAP-70激酶的相互作用机制。
2. **文献名称**：*Structural Insights into SLP-76 (LCP2) Oligomerization via Recombinant Protein Crystallography*
**作者**：Martinez R, Kim S, et al.
**摘要**：通过昆虫细胞表达系统获得高纯度重组LCP2蛋白，结合X射线晶体学解析其寡聚化结构，提出其通过SAM结构域介导的自组装对免疫突触形成的关键作用。
3. **文献名称**：*Functional Rescue of LCP2-Deficient Cells by Recombinant Protein Delivery*
**作者**：Nguyen T, Patel D, et al.
**摘要**：开发了一种基于HEK293细胞的重组LCP2蛋白生产方法，证明外源性重组蛋白可通过脂质体转染恢复LCP2缺陷型Jurkat细胞的IL-2分泌功能，为基因缺陷疾病提供潜在治疗策略。
4. **文献名称**：*High-Throughput Screening of LCP2-Binding Drugs Using a Recombinant Protein Platform*
**作者**：Gupta M, et al.
**摘要**：构建了基于重组LCP2蛋白的体外药物筛选平台，鉴定出多个小分子抑制剂可阻断LCP2与Vav1的结合，为过度免疫反应的调控提供了候选化合物。
---
**提示**：实际研究中建议通过PubMed或Google Scholar以关键词“LCP2 recombinant”、“SLP-76 expression”或结合具体应用方向(如“signaling”、“structure”)检索最新文献，并优先选择高影响力期刊(如*Nature Immunology*、*Journal of Biological Chemistry*)以获取权威信息。
LCP2 (Lymphocyte Cytosolic Protein 2), also known as SLP-76 (SH2 domain-containing leukocyte protein of 76 kDa), is a critical adaptor protein involved in intracellular signaling within immune cells, particularly T cells and mast cells. It was first identified in the mid-1990s as a key mediator of immunoreceptor signaling pathways. Structurally, LCP2 contains three functional domains: an N-terminal acidic region, a central proline-rich region, and a C-terminal SH2 domain. These domains enable interactions with multiple signaling molecules, including LAT (Linker for Activation of T cells), ZAP-70 (Zeta-chain-associated protein kinase 70), and PLCγ (phospholipase C gamma), facilitating signal transduction downstream of T-cell receptor (TCR) activation.
Recombinant LCP2 proteins are engineered through genetic modification to express and purify the protein in vitro, typically using bacterial, insect, or mammalian expression systems. These engineered proteins retain functional domains and are widely used to study immune cell activation mechanisms. For instance, recombinant LCP2 has been instrumental in elucidating its role in coordinating the assembly of signaling complexes that regulate cytokine production, cell proliferation, and immune response modulation. Researchers also employ it to investigate pathological conditions, such as autoimmune diseases and immunodeficiency disorders, where LCP2 dysfunction is implicated.
Beyond basic research, recombinant LCP2 serves as a tool for drug discovery, particularly in screening compounds targeting T-cell signaling pathways. Its application extends to diagnostic development for immune-related diseases. Studies using knockout models have highlighted LCP2's non-redundant role in adaptive immunity, further underscoring its biomedical relevance. Ongoing research continues to explore its interactions in signaling networks, aiming to develop targeted therapies for immune regulation.
×
